WO2003000695A8 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrrolopyrimidines as protein kinase inhibitors

Info

Publication number
WO2003000695A8
WO2003000695A8 PCT/GB2002/002835 GB0202835W WO03000695A8 WO 2003000695 A8 WO2003000695 A8 WO 2003000695A8 GB 0202835 W GB0202835 W GB 0202835W WO 03000695 A8 WO03000695 A8 WO 03000695A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolopyrimidines
protein kinase
kinase inhibitors
compounds
prodrugs
Prior art date
Application number
PCT/GB2002/002835
Other languages
French (fr)
Other versions
WO2003000695A1 (en
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Chris Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Iain Mcfarlane Mclay
David John Aldous
Original Assignee
Aventis Pharma Inc
Paul Joseph Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Chris Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Iain Mcfarlane Mclay
David John Aldous
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0210652-3A priority Critical patent/BR0210652A/en
Priority to UA2004010502A priority patent/UA76760C2/en
Application filed by Aventis Pharma Inc, Paul Joseph Cox, Tahir Nadeem Majid, Shelley Amendola, Stephanie Daniele Deprets, Chris Edlin, Brian Leslie Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin, Iain Mcfarlane Mclay, David John Aldous filed Critical Aventis Pharma Inc
Priority to APAP/P/2003/002929A priority patent/AP2003002929A0/en
Priority to JP2003507098A priority patent/JP4344607B2/en
Priority to IL15950602A priority patent/IL159506A0/en
Priority to EEP200400003A priority patent/EE05432B1/en
Priority to CA002451932A priority patent/CA2451932C/en
Priority to MXPA03011998A priority patent/MXPA03011998A/en
Priority to EP02740895A priority patent/EP1404676A1/en
Priority to EA200400073A priority patent/EA007415B1/en
Priority to YU99203A priority patent/RS51698B/en
Priority to NZ529766A priority patent/NZ529766A/en
Priority to AU2002314325A priority patent/AU2002314325B8/en
Priority to KR1020037016809A priority patent/KR100875380B1/en
Priority to MEP-193/08A priority patent/MEP19308A/en
Priority to HU0400300A priority patent/HUP0400300A3/en
Priority to SK1588-2003A priority patent/SK15882003A3/en
Publication of WO2003000695A1 publication Critical patent/WO2003000695A1/en
Priority to HR20031049A priority patent/HRP20031049A2/en
Priority to NO20035728A priority patent/NO20035728L/en
Priority to IL159506A priority patent/IL159506A/en
Priority to US10/744,478 priority patent/US7259154B2/en
Publication of WO2003000695A8 publication Critical patent/WO2003000695A8/en
Priority to HK05100184A priority patent/HK1068134A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention is directed to compounds of the formula (I) to N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and to methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.
PCT/GB2002/002835 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors WO2003000695A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
AU2002314325A AU2002314325B8 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
NZ529766A NZ529766A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
APAP/P/2003/002929A AP2003002929A0 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
UA2004010502A UA76760C2 (en) 2001-06-23 2002-06-21 Pyrrole pyrimidines as protein kinase inhibitors
IL15950602A IL159506A0 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EEP200400003A EE05432B1 (en) 2001-06-23 2002-06-21 P rrolop rimidines as protein kinase inhibitors
KR1020037016809A KR100875380B1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidine as a Protein Kinase Inhibitor
MXPA03011998A MXPA03011998A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors.
EP02740895A EP1404676A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EA200400073A EA007415B1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
YU99203A RS51698B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
BR0210652-3A BR0210652A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
JP2003507098A JP4344607B2 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
CA002451932A CA2451932C (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
MEP-193/08A MEP19308A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
HU0400300A HUP0400300A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
SK1588-2003A SK15882003A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
HR20031049A HRP20031049A2 (en) 2001-06-23 2003-12-17 Pyrrolopyrimidines as protein kinase inhibitors
NO20035728A NO20035728L (en) 2001-06-23 2003-12-19 Pyrrolopyrimidines as protein kinase inhibitors
IL159506A IL159506A (en) 2001-06-23 2003-12-22 Pyrrolopyrimidines as protein kinase inhibitors
US10/744,478 US7259154B2 (en) 2001-06-23 2003-12-23 Pyrrolopyrimidines
HK05100184A HK1068134A1 (en) 2001-06-23 2005-01-10 Pyrrolopyrimidines as protein kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
GB0115393.1 2001-06-23
US30167801P 2001-06-28 2001-06-28
US60/301,678 2001-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/744,478 Continuation US7259154B2 (en) 2001-06-23 2003-12-23 Pyrrolopyrimidines

Publications (2)

Publication Number Publication Date
WO2003000695A1 WO2003000695A1 (en) 2003-01-03
WO2003000695A8 true WO2003000695A8 (en) 2004-03-11

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002835 WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
SG176311A1 (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
MXPA06005882A (en) * 2003-11-25 2006-06-27 Pfizer Prod Inc Method of treatment of atherosclerosis.
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (en) 2006-10-09 2010-02-25 武田薬品工業株式会社 Kinase inhibitor
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
WO2009098715A2 (en) 2008-01-11 2009-08-13 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
PE20140407A1 (en) 2008-06-10 2014-04-25 Abbott Lab NEW TRICYCLIC COMPOUNDS
US8426411B2 (en) 2008-06-10 2013-04-23 Abbott Laboratories Tricyclic compounds
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
PE20130216A1 (en) 2010-05-21 2013-02-27 Incyte Corp TOPICAL FORMULATION FOR A JAK INHIBITOR
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
EP2838898B1 (en) 2012-04-20 2017-01-18 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
ES2609126T3 (en) 2012-07-26 2017-04-18 Glaxo Group Limited 2- (Azaindol-2-yl) benzimidazoles as PAD4 inhibitors
AU2013312477B2 (en) * 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
EP2970268A1 (en) 2013-03-13 2016-01-20 AbbVie Inc. Cdk9 kinase inhibitors
CN105189481A (en) 2013-03-13 2015-12-23 艾伯维公司 Pyridine cdk9 kinase inhibitors
WO2014160028A1 (en) * 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
WO2014139328A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
AU2014231567A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US20190046527A1 (en) 2017-03-09 2019-02-14 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
CN112105608B (en) 2018-01-30 2023-07-14 因赛特公司 Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one
AU2019245420A1 (en) 2018-03-30 2020-11-12 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
CN113490668A (en) 2018-10-05 2021-10-08 安娜普尔纳生物股份有限公司 Compounds and compositions for treating diseases associated with APJ receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217873T1 (en) * 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
KR20000057228A (en) * 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 Fused bicyclic pyrimidine derivatives
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
EA005852B1 (en) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
SK3852001A3 (en) * 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
CN1195755C (en) * 1999-12-10 2005-04-06 辉瑞产品公司 Pyrrolo [2,3-d] pyrimidine compounds

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1

Also Published As

Publication number Publication date
OA12632A (en) 2006-06-14
CA2451932A1 (en) 2003-01-03
JP2005508300A (en) 2005-03-31
NZ529766A (en) 2008-11-28
MEP19308A (en) 2010-06-10
PL374096A1 (en) 2005-09-19
CN1518552A (en) 2004-08-04
RS99203A (en) 2006-12-15
AU2002314325B2 (en) 2009-01-08
CA2451932C (en) 2009-12-29
CN1294135C (en) 2007-01-10
RS51698B (en) 2011-10-31
JP4344607B2 (en) 2009-10-14
EE05432B1 (en) 2011-06-15
EA200400073A1 (en) 2004-08-26
HUP0400300A2 (en) 2007-08-28
AU2002314325B8 (en) 2009-01-29
HUP0400300A3 (en) 2010-12-28
CZ20033443A3 (en) 2004-03-17
EA007415B1 (en) 2006-10-27
EP1404676A1 (en) 2004-04-07
EE200400003A (en) 2004-02-16
TNSN03144A1 (en) 2005-12-23
BR0210652A (en) 2004-08-10
UA76760C2 (en) 2006-09-15
WO2003000695A1 (en) 2003-01-03
SK15882003A3 (en) 2004-07-07
GB0115393D0 (en) 2001-08-15
ECSP034922A (en) 2004-04-28
TR200302242T2 (en) 2004-12-21

Similar Documents

Publication Publication Date Title
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
YU84603A (en) Novel tyrosine kinase inhibitors
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
GB0112348D0 (en) Compounds
WO2004005281A8 (en) Inhibitors of tyrosine kinases
WO2006011050A3 (en) Pyridine derivatives
MXPA02005844A (en) Inhibitors of protein kinases.
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
HK1065540A1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MXPA03010761A (en) Pharmaceutical combinations.
WO2002018321A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
DE50211929D1 (en) Pyrimidinderivate
MXPA04003611A (en) Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
WO2003051838A3 (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-992/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: DZP2003000281

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 529766

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/09315

Country of ref document: ZA

Ref document number: 1-2003-501226

Country of ref document: PH

Ref document number: 200309315

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002929

Country of ref document: AP

ENP Entry into the national phase

Ref document number: 10845302

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 028119320

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2003-3443

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20031049A

Country of ref document: HR

Ref document number: 2451932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002314325

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 15882003

Country of ref document: SK

Ref document number: PA/A/2003/011998

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 159506

Country of ref document: IL

Ref document number: 374096

Country of ref document: PL

Ref document number: 2030/CHENP/2003

Country of ref document: IN

Ref document number: 1200301156

Country of ref document: VN

Ref document number: 2003507098

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/02242

Country of ref document: TR

Ref document number: 10744478

Country of ref document: US

Ref document number: 1020037016809

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002740895

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400073

Country of ref document: EA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 01/2003 UNDER (75) REPLACE "ALDOUS, DAVIS, JOHN" BY "ALDOUS, DAVID, JOHN"

WWP Wipo information: published in national office

Ref document number: PV2003-3443

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002740895

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 01/2003 UNDER (72, 75) REPLACE "AMENDOLA, SHELLEY" BY "AMENDOLA, SHELLEY" AND "MCLAY, LAIN, MCFARLANE" BY "MCLAY, IAIN, MCFARLANE.